

Index

a

active pharmaceutical ingredients (APIs) 422
 activity-specific subpockets 92
 ADAPT program 107
 adaptive biasing force (ABF) 387
 adaptive molecular design 12
 adenosine receptor (AR) 237
 AllChem 350
 AlleGrow 111, 115
 AMBER program 103
 amino acids 470–471
 ant colony optimization 449–450
 – and MHC-I binding peptides 450–456
 antitarget activity reduction 296–298
 artificial neural network 27, 443
 associative networks 27
 Astex “Rule of Three” 150
 atom-based methods 101–103
 atom property fields (APFs) 90–94
 atomic force microscopic (AFM) 513
 AutoGrow 107

b

backbone cyclization 456–457
 basic products 250
 Bayes theorem 26
 Bennett’s acceptance ratio (BAR) 386
 BICLAIM database 350–351
 – application example 360–366
 – focused libraries design 359
 – fragment space 352–355
 – FTrees fragment space search 356
 – general workflow 351–352
 – query 355–356
 – scaffold selection 356–358
 bioactive conformation 18
 bioactivity estimation 207
 biochemical assay screening 157–158

bioisosteres 417
 – exemplar applications
 – – Drug Guru 429–431
 – – information-based bioisosteric replacement 427
 – – SkelGen 431–433
 – and isosterism, history of 418–420
 – replacement methods 421–422
 – – databases 422–424
 – – molecular shape 426–427
 – – molecular topology 426
 – – physicochemical properties 424–426
 biolayer interferometry (BLI) 160–161
 biophysical assay techniques 160–161
 biophysical technique 155
 BIOSTER database 422, 426
 Boltzmann distribution 473
 BOMB program 104
 Bongard problem 10
 Born–Oppenheimer approximation 5
 BREED method 177
 BRICS (breaking of retrosynthetically interesting chemical substructures) 333–334

c

caDNAno 506
 caDNAnoSQ 506
 CAESA (computer assisted estimation of synthetic accessibility) program 33, 269
 Cambridge Crystallographic Data Centre (CCDC) 422
 Cambridge Structure Database (CSD) 422–423
 CANADA program 503
 cascaded neural network model 28
 CASREACT (Chemical Abstracts Reaction Search) 270

- CATS (chemically advanced template search) 338, 350, 426
- CHARMm 104
- ChEMBL database 289–293, 295, 301, 318, 423–424
- Chemical Abstracts Service (CAS) 268, 328
- Chemical Genesis program 107, 108
- chemical similarity 9, 20
- chemical space 3, 326–327
- assessment, and focused set of reactions 251–254
 - complexity enumerating and sampling 61, 63–65
 - models 4
 - searching 105–108
 - size estimation 327–328
 - subspaces enumeration 328–330
- ChemSpace technology 350
- chromosomes 277
- cloverleaf 529
- COALESCE 240
- cofactors and nonbiological protein assemblies 480–481
- COLIBREE 338
- CoLibri 335, 352
- combinatorial space 325–326, 330–331
- chemical space 326–327
 - – chemical subspaces enumeration 328–330
 - – size estimation 327–328
 - generation 332
 - – computational space from chemical knowledge 334–335
 - – from fragmentation 332–334
 - manipulation 335–336
 - querying 336
 - – applications 340–341
 - – fragment spaces 337–339
 - – Markush structures 341–342
 - – reaction-based combinatorial spaces 339–340
 - visualization 342
- CoMFA (comparative molecular field analysis) 218–222, 235, 341
- complexity model, in molecular design 57–58
- chemical space complexity enumerating and sampling 61, 63–65
 - emergent behavior 74–75
 - enhancements 60–61
 - information content as factor in *de novo* design 69–72
 - molecular interactions 58–60
 - reductionism and drug design 67–69
 - thermodynamic entropy and drug design 73–74
 - validation 65–67
- compound construction strategies 30–33
- compound scoring strategies 33–35
- ligand-based scoring 37
 - receptor-based scoring 35–37
- computer-aided design (CAD) tools 506
- computer docking 128
- CONCEPTS program 103
- CONCERTS program 108
- Congreve's rule of threes 127, 131
- Connolly algorithm 7
- Connolly surface 7
- consensus scoring 108–109
- continuous spatial function 6
- Contour algorithm 111, 115
- CORINA 313, 428
- Crooks equation 380
- cumulant expansion 381
- d**
- 3D-QSAR approaches 215–216
- current methods 216–217
 - Leapfrog 217–219
 - recent advances 219–222
- D4 receptor potency optimization 301
- dead-end elimination (DEE) 474–475
- decision space 452–453
- diversity selection algorithms 153
- DNA-branched structures 499
- alternative designs 511–514
 - DNA junctions *de novo* design 499–504
 - scaffolded DNA origami design 505–511
 - tile-to-tile bonding 504–505
- DNA origami 498, 499
- scaffolded design 505–506
 - – multilayer 509–511
 - – three-dimensional structures 509
 - – two-dimensional structures 506–509
- DOGS software 41, 42, 249, 255, 270, 340
- donepezil 296, 301
- DREAM++ 33
- druggability 162–163
- Drug Guru 429–431
- drug-like compounds construction, by Markov chains 311–313
- applications 314
 - – BACE-1 inhibitors design with FOG 316–319
 - – FOG compounds target class prediction 314–316
 - FOG algorithm and library generation 313
- drug-likeness assessment 207

- DrugScore 109
 dummy products 340
 DyoBlock 104
- e**
- e-LEA3D 104
 E-NoVo (Enumerated *de NoVo* design) 104
 electrophoretic mobility shift assay-SELEX (EMSA-SELEX) 525
 emergent behavior 74–75
 EMIL (Example-Mediated Innovation for Lead Evolution) 422
 empirical scoring functions 36, 109
 end capping 458–459
 energy functions 471–472
 energy landscape theory 468–469, 472–473, 478, 485
 enthalpy 16
 entropy 16
 entropy-based formalism 476
 evolution strategy 13, 14
 evolutionary algorithms 106–107, 276–277, 294–295, 444–446
 – multiobjective approaches 108
 EVOscreen™ HTS 158
 Evotec EVOsource database 153
 exit vectors 341
- f**
- F-DycoBlock 104
 feature trees fragment space (FTreesFS) 337–338, 349–352, 354–357, 359, 361, 366
 feedforward networks 27
 ferritin proteins 485
 fidelity, of structure 502
 FieldAlign 428
 fit quality (FQ) 166
 fitness function 440, 443–445, 450, 453, 456, 460
 fitness landscapes 9–10
 – modeling 21–26
 – – artificial neural network 27
 – – Gaussian process 28–30
 – – naïve Bayes classifier 26–27
 – – support vector machine (SVM) 27–28
 FLARM (flexible atom receptor model) 231, 235–236
 FlexNovo program 104, 340
 FlexX molecular docking software 104, 108
 fluorescence correlation spectroscopy (FCS) 155
 Flux 149
 FNY327 126
 foldability criteria and negative design 472–473
 force-field based scoring functions 108
 four-base code 495, 500
 fragment-assisted drug discovery (FADD) 182
 fragment-based approaches 31–32
 fragment-based design, of focused compound libraries 349–351. *See also* BICLAIM database
 fragment-based drug design (FBDD) 125, 144–148, 375–376
 – detection methods 132–134
 – final products 137–138
 – high-throughput screening (HTS) 126, 129
 – – optimization 130
 – – small-molecule library design 126–129
 – – target identification 126
 – library generation 130–131
 – – computational techniques for library refinement 132
 – optimization 135–137
 – screening 134–135
 fragment-based methods 101–105
 fragment binding energies. *See* superadditivity
 fragment evolution 165
 fragment library 332
 fragment-linking principles 177–182
 fragment merging 165, 175–177
 fragment molecular orbital (FMO) 164, 168, 173
 fragment optimized growth (FOG) 311–312
 – BACE-1 inhibitors design 316–319
 – compounds target class prediction 314–316
 – and library generation 313
 Fragment Shuffling 104
 fragment space 332, 335
 fragment trees 338
 “Frankenstein” approach to drug discovery 175
 free-energy methods, in ligand design 373
 – best practices 396–397
 – calculation and choice of method 382–385
 – current issues 385–387
 – experimental data 385
 – *in silico* binding affinity methods 377
 – – free energy perturbation (FEP) 378–379
 – – linear interaction energy (LIE) 381
 – – MM-PBSA and MM-GBSA 382
 – – nonequilibrium approaches 380–381
 – – potential of mean force (PMF) calculations 379–380

- free-energy methods, in ligand design (*contd.*)
 - – thermodynamic integration and alchemical transformations 377–378
 - in lead optimization (LO) 373–374
 - – as emerging tool in industry 374–375
 - – in fine-tuning ligand discovery 375–377
 - practical examples 387
 - – application to pharmaceutically relevant systems 389–396
 - – model systems and studies 387–388
 - free energy perturbation (FEP) 378–379
 - versus linear interaction energy (LIE) 383
 - versus potential of mean force (PMF) 383
 - versus thermodynamic integration (TI) 384
 - functional/high-concentration screening 132–133
- g**
- GA algorithm 106, 107
 - GANDI program 107–108
 - Gaussian process 28–30
 - Gedanken experiment 10
 - generated databases (GDBs) 268, 329–330
 - genetically evolved receptor models (GERMs) 232, 238
 - GENG algorithm 329
 - GenStar program 102–103
 - GeometryFit program 109
 - Gibbs energy 16
 - GIDEON program 503
 - GOLD docking software 154
 - G-protein-coupled receptor (GPCR) 84, 87, 91, 228, 240, 252, 254, 316
 - libraries 149
 - GRID program 69, 163
 - GROMACS 104
 - GroupBuild 103–104, 108
 - group efficiency (GE) 166
 - GrowMol program 102–103, 115
- h**
- halogen-enriched fragment libraries (HEFLibs) 152
 - Hartree–Fock method 5
 - high-throughput screening (HTS) 61, 63–65, 125–126, 129, 349–350, 360, 375, 376
 - optimization 130
 - small-molecule library design 126–129
 - target identification 126
 - history, of *de novo* drug design 37–42
 - hit and lead identifications, from fragments 143
 - fragment-assisted drug discovery (FADD) 182
 - fragment-based drug design (FBDD) 144–148
 - fragment hit expansion and fragment evolution 170–175
 - fragment library design incorporating computational methods 148
 - – focused sets 154
 - – fragment optimization designing 154–155
 - – molecular attributes and physicochemical properties 150–151
 - – screening methods influence on library selection 151
 - – size of library and diversity 152–153
 - – strategies 148–150
 - – undesirable functionality removal 152
 - fragment-linking principles 177–182
 - fragment merging principles 175–177
 - fragment prioritization for optimization 165
 - – computational and thermodynamic methods for fragment selection and prioritization 167–170
 - – efficiency metrics 165–167
 - fragment screening 155
 - – biochemical assay screening 157–158
 - – biophysical assay techniques 160–161
 - – fragment library screening using computational methods 161–162
 - – isothermal titration calorimetry (ITC) 160
 - – ligandability screening using fragments 162–165
 - – membrane proteins assay techniques 161
 - – NMR screening 156–157
 - – SPR screening 157
 - – thermal shift assays 158
 - – X-ray crystallography screening 155–156
 - HSITE 101
 - Hückel theory of molecular orbitals 5
 - human pocketone 79
 - compound activity prediction by ligand-pocket docking and scoring 87
 - – optimizing pocket sets for reliable results 87–88
 - – unusually large and multifunctional pockets 88–90
 - diversity and redundancy 85–86

- ligands clustering by functions and subpockets 92–94
- pocketome-derived 3D chemical fields as activity prediction models 90–92
- predicted pockets 79–83
- validated compilation 83–85
- hydrogen bonding 17–18
- hydrophobic effect 18
- hysteresis 379

i

- IADE (information automatic design) 427
- icmPocketFinder 79–82
- indole library 353
- intelligence amplification (IA) 70
- interligand nuclear Overhauser effect (ILOE) 156
- ISOAK similarity measure 340
- isothermal titration calorimetry (ITC) 160

j

- Jarzynski's equality (JE) 380, 381

k

- Kemp elimination 478
- kernel trick 27, 40
- k*-nearest neighbor technique 27
- KNIME ((Konstanz Information Miner) tool 274–275, 280–281
- knowledge-based scoring functions 36, 109
- known drug space (KDS) 327, 328

l

- Laplacian-modified naive Bayesian (LMNB) model 291–292
- LEA3D algorithm 104, 107–108, 115
- Leapfrog 217–219
- leave-one-out (LOO) cross-validation 233
- LEGAND program 102
- LEGEND program 108
- Lennard-Jones potential 79
- leucine zipper (bZIP) 479
- libDOGS software 257–258
- library encoding schemes 249–250
- ligandability screening, using fragments 162–165
- ligand-based molecular design 227–231
 - pseudoreceptor algorithms 231–232
 - successful applications 232–240
- ligand-based scoring 37
- ligand-based topological pharmacophore (LBTP) 426
- ligand-binding cavities 79
- ligand efficiency (LE) 21, 135

- ligand-efficiency-dependent lipophilicity (LELP) 167
- ligand-induced structure-activity relationship display (LiSARD) 23
- ligand lipophilicity efficiency (LLE/LiPE) 167
- ligand lipophilicity efficiency AT (LLE_{AT}) 167
- LigBuilder 39, 104, 113–115
- LigPrep 313
- LigSite 163
- linear interaction energy (LIE) 381
 - versus FEP/TI 383
- Lipinski's rule of fives 127, 131, 137, 207, 212. *See also* Rule of 5
- lipocalins 480
- lipophilic ligand efficiency 21
- lipophilicity 57, 66, 72–73
- local optimization 11
- LoFT (library optimizer using feature trees) 335–336
- LUDI program 103, 109, 111–113
- LY-517717 (Eli Lilly) 110–111

m

- Markush structures 331
- mass spectrometry (MS) 133
- matched molecular pairs (MMPs) 423
- maximum common substructure (MCS) 290–291
- MCDNLG program 106
- mean field theory 475
- MED-Hybridize 104
- MED-Portions 104
- MEGA program 108, 115, 280
- melting curves 502
- membrane proteins 481–483
 - assay techniques 161
- metadynamics 387
- Metropolis Monte Carlo 106
- mirror image chemistry 534
- MM-PBSA and MM-GBSA versus FEP/TI 383
- MOGA (multiobjective genetic algorithm) 278–279
- molecular design cycle 9–14
- molecular docking 154
- molecular fingerprints 314, 316
- molecular representation 1–9
- molecular surfaces 6
- MolTransformer node 275, 280
- Monte Carlo-based methods 106
- Monte Carlo methods 473–474, 529
- Morgan algorithm 71
- MoSELECT program 279

- multidimensional scaling (MDS) 23
 - multilayer perceptrons (MLPs) 27
 - multiobjective *de novo* design 279–282
 - multiobjective *de novo* design, of synthetically accessible compounds 267–270
 - using evolutionary algorithms 276–277
 - multiobjective *de novo* design 279–282
 - multiple objectives optimization 277–279
 - using reaction vectors 270–275
 - multiobjective evolutionary algorithm (MOEA) 40
 - multiple copy simultaneous search (MCSS) 101, 163
 - multitarget profiles and ligands *de novo* design 287–289
 - antitarget activity reduction 296–298
 - D4 receptor potency optimization 301
 - evolutionary algorithm 294–295
 - experimental validation 295–297
 - ligand design creativity automation 289–293
 - novel ligands designing to defined profile 301, 303–304
 - Muse program 218–223
- n**
- naïve Bayes classifier 26–27
 - naïve Bayesian models 314
 - Nano-Engineer-1 program 503
 - NanoEngineering-1 506
 - NAUTY software 330
 - negative design 11, 23
 - NEWLEAD program 105
 - NSGA-II algorithm (nondominated sorting genetic algorithm) 279–280
 - nuclear magnetic resonance (NMR) 61, 73, 133–134, 156–157, 470, 477–479, 481–483
 - nucleic acid structures 495–499
 - alternative DNA designs 511–514
 - DNA-branched structures 499
 - DNA junctions *de novo* design 499–504
 - tile-to-tile bonding 504–505
 - scaffolded DNA origami design 505–506
 - multilayer DNA origami 509–511
 - three-dimensional structures 509
 - two-dimensional structures 506–509
- o**
- octet rule 418
 - OpenEye docking 87
 - open molecule generator (OMG) 330
 - orthogonal screening approach 155
- p**
- P450 CYP121 inhibitor 175, 176
 - pairwise interaction energies (PIEs) 173
 - pan assay interference compounds (PAINS) 152
 - Pareto frontier 278
 - Pareto ranking 278, 280, 293
 - PARM (pseudoatomic receptor model) 232, 233
 - partial least squares 215
 - particle swarm optimization 446, 448–449
 - peptide design by nature-inspired algorithms 437
 - chemical modification 456
 - backbone cyclization 456–457
 - end capping 458–459
 - stapling 458
 - sugar coating 459–460
 - MHC-I binding peptides, by ant colony optimization 450–456
 - optimization 441–444
 - ant colony optimization 449–450
 - evolutionary algorithms 444–446
 - particle swarm optimization 446, 448–449
 - template-based design 437–441
 - pharmacophore-based *de novo* design 201–202
 - v1.0
 - basic scheme 202
 - fragment and linker databases 203–204
 - fragments connection by linkers 205–206
 - fragments mapping 204
 - generated molecules assessments 206–208
 - v2.0 updated version modifications 208–209
 - designated fragment 209
 - molecular construction process conformation optimization 209–210
 - two pharmacophore features sharing one fragment 210
 - validation 210–212
 - pharmacophore-based methods 105
 - pharmacophore searching 129
 - PharmHand™ software 129
 - PhDD program 108
 - phenotypic screening 264
 - phenprocoumon 146
 - pheromone matrix 452
 - photoaptamers 525
 - photo-SELEX approach 525
 - PI3Kγ inhibitor 175, 176

- plane of best fit (PBF) 150–151
 PLANTS program 104
 PLX4720 147
 PNU-103017 146
 PNU-96988 146–147
 polymerase chain reaction (PCR) 522, 524, 534
 polypharmacological fitness landscapes 23, 25
 positive design 11, 23
 potential of mean force (PMF) 109
 – calculations 379–380
 – versus FEP 383
 – versus TI 383–384
 PPAR γ 80–82, 88–90, 92–94
 PrGen software 231, 232, 237, 238
 principal components analysis (PCA) 22, 63
 PRO_SELECT 110
 probabilistic approach 475–477
 projection to latent structures (PLS) 22
 PRO-LIGAND 104
 promiscuity 66–67, 72, 84
 prostate-specific membrane antigen (PSMA) 522
 Protein Data Bank (PDB) 83, 84, 97, 104, 531
 protein design 467–469
 – catalysis redox activity, and enzymes, 477–478
 – – cofactors and nonbiological protein assemblies 480–481
 – – *de novo* design and redesign 478–479
 – – membrane proteins 481–483
 – – protein–protein interactions and protein assemblies 483–485
 – – protein reengineering 479–480
 – elements 470
 – – amino acids 470–471
 – – energy functions 471–472
 – – foldability criteria and negative design 472–473
 – – sequence search and characterization 473–477
 – – side-chain conformations 471
 – – solvation 472
 – – target structures 470
 protein–ligand complex 103, 104, 109
 protein–ligand crystal structures 59, 68, 69, 73
 protein–ligand surface interaction analysis (PLSIA) program 240
 protein–protein interaction inhibitor (PPII) 172
 protein–protein interactions (PPIs) 163–165, 171–173
 protein reengineering 479–480
 pseudohalogens 419
 pseudoreceptor algorithms 231–232
 pseudoreceptor point similarity (PRPS) 239
 PubChem 330
- q**
 quantitative structure–activity relationship (QSAR) 29, 69, 150
 Quasar algorithms 238
- r**
 rank, of structure 500
 rapid (elimination of swill) approach 22
 RASSE program 103, 108
 reaction-driven *de novo* design 245–247
 – of chemical libraries addressing target families 256–261
 – successful applications 254–256
 – synthetic feasibility problem tackling 247–249
 – – electronic laboratory notebooks 249–251
 – – focused set of reactions chemical space assessment 251–254
 reaction vectors 270–275, 280–282
 reagent clipping 353–354
 RECAP (retrosynthetic combinatorial analysis procedure) 33, 149, 154, 269, 333, 335, 338, 341, 350
 receptor-based scoring 35–37
 receptor–ligand interaction 14–21
 ReCore 149, 340–341
 recurrent networks 27
 reductionism and drug design 67–69
 REOS (rapid elimination of swill) 152
 REPLACE method 172
 retrosynthetic fragmentation 332
 R-groups 341
 riboswitches 520–521
 RNA aptamer design 519
 – functional analyses (*in vitro* and *in vivo*) 532–533
 – future perspectives 535–536
 – problems 533–535
 – riboswitches 520–521
 – SELEX 521–522
 – – method 522–525
 – – speeding up by computational methods 526–530
 – – technical challenges and recent developments 526
 – structures and probing methods 530–532

- RNA interference (RNAi) 520
 ROCS (rapid overlay of chemical structures) 161–162, 356, 357, 362, 363
 rotatable bond 207
 roulette-wheel selection algorithm 206
 Route Designer 33
 rubredoxin 478
 Rule of 5 326–327. *See also* Lipinski's rule of fives
- S**
 SARSE 506
 scaffold 252–254, 259–260, 329, 499
 – selection 356–358
 Schrödinger equation 4, 5
 Scientific Vector Language (SVL) 170
 scoring methods 108–109
 selective optimization of side activities (SOSAs) 295
 self-organizing map (SOM) 23, 456
 sequence symmetry minimization principle 501–503
 SEQUIN program 499–503
 Shannon entropy 70–71, 73, 441
 SHAPE chemistry 532
 SHAPES library 149, 154
 side-chain conformations 471
 similar property principle 424
 simulated molecular evolution (SME) 445, 448
 single-stranded DNA (ssDNA) 495, 499, 505, 511–513
 site identification by ligand competitive saturation (SILCS) method 163
 size-independent ligand efficiency (SILE) 166
 SkelGen program 105, 431–433
 small molecule growth (SMoG) algorithm 311–312
 SMARTS Reaction 251
 SMILES 313, 356, 360, 429
 SMIRKS 270, 271, 275, 429
 SMoG program 102, 109
 social memory 446
 solvation 472
 solvent-accessible surface (SAS) 6–7
 spherical harmonics 8–9
 spiegelmers 534
 SPLICE program 105
 SPROUT 110, 269
 staple strands 505
 stapling 458
 StarDrop 292, 296
 statistical potential based scoring functions. *See* knowledge-based scoring functions
 steered molecular dynamics (SMD) 380–381
 stochastic algorithm 13–14
 stochastic proximity embedding (SPE) 23
 strong causality 9, 445
 β -structures 478
 structure–activity relationship (SAR) 1, 3, 4, 9–10, 23, 245, 256, 358–359. *See also* ligand-based molecular design
 structure-based *de novo* drug design (SBDND) 97–99
 – current progress in methodologies 99
 – – binding site identification 100–101
 – – chemical space searching 105–108
 – – molecular design 101–105
 – – scoring methods 108–109
 – – synthetic accessibility 110
 – recent applications 110–114
 structure-based drug design (SBDD) 145, 227–229, 241
 structure kinetic relationship (SKR) 157
 structure-thermodynamic relationships (STRs) 160
 sub-substructures (SSSs) 338
 sugar coating 459–460
 superadditivity 180
 support vector machine (SVM) 27–28
 surface plasmon resonance (SPR) 61, 133, 151, 157
 – SPR-SELEX 524
 SYBL 217
 SYLVIA program 33, 110
 SYNOPSIS 33, 110, 247, 249, 255, 270, 339–340
 synthetic accessibility 110
 – assessment 207–208
 Systematic Evolution of Ligands by EXponential Enrichment (SELEX) 521–522
 – method 522–525
 – speeding up by computational methods 526–529
 – – design of structures 529–530
 – technical challenges and recent developments 526
- T**
 tailored-SELEX 525
 target-immobilized NMR screening (TINS) 151
 tenascin 479
 theoretical fragment linker factor 180

- thermal shift assay 158
 - (fluorescence-based) 133
- thermodynamic entropy and drug design 73–74
- thermodynamic integration (TI)
 - and alchemical transformations 377–378
 - versus FEP 384
- thioredoxin 477
- TIBCO Spotfire 259, 262–263
- tile-to-tile bonding 504–505
- Tipranavir 145–147
- toggle-SELEX 525
- TOPAS software 39, 247, 350
- TopClass algorithm 317–318
- topomers 221–223, 341
- triose phosphate isomerase (TIM) barrel family 470, 478

- u**
- umbrella sampling 379
- Uniquimer 3D program 503–504
- untranslated region (UTR) 520
- Urbild 3–5

- v**
- Vemurafenib 147
- virtual screening 375–376, 382, 383, 396, 397
- VTP-27999 (Vitae Pharmaceuticals) 111–113

- w**
- WaterMap 261
- Watson–Crick base pairing rule 495, 496, 499
- weave tiles 513
- weighted histogram analysis method (WHAM) 379, 387
- WhichDock™ 128

- x**
- X-Cscore 109
- X-ray crystallography 61, 134, 470, 485, 531
 - screening 155–156

- z**
- ZINC database 131

